Exelixis Eyes Liver Cancer OK To Help Drive Cabometyx Sales

 
• By Kevin Grogan

Exelixis is looking to get its kidney cancer drug Cabometyx approved for hepatocellular carcinoma as well, but the therapy's long-term success is reliant on combinations with checkpoint inhibitors

Milky Way. Night sky with stars and silhouette of a man with raised-up arms.
CELESTIAL data could get Exelixis another approval for Cabometyx • Source: Shutterstock

More from Anticancer

More from Therapy Areas